Affiliation:
1. Clinical Oncology Dispensary no. 1
2. Kuban State Medical University
3. Kuban State Medical University; Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1
Abstract
Currently, there are limited data supporting the use of parathyroid hormone-related protein for the purposes of breast cancer detection and disease prognosis. This literature review covers research results on diagnostic potential of parathyroid hormone-related protein as a biomarker for breast cancer, as well as the information available in the scientific literature, reflecting obvious contradictions regarding clinical and prognostic importance of this protein in the primary breast cancer, correlation of its expression with the risk of bone metastasis and survival of patients. Results of preclinical and clinical research show, that parathyroid hormone-related protein inhibits tumor progression and decreases its metastasis at early stages of the disease, which improves the survival rate, but it has an opposite effect at the advanced stages of cancer, as it increases tumor development and metastasis, and reduces survival rates. Altogether, these studies prove an idea that parathyroid hormone-related protein plays a double role in breast cancer. Use of parathyroid hormone-related protein for breast cancer early detection and disease prognosis is currently becoming a subject of detailed scientific research studies, which is confirmed by the facts presented in this literature review.
Publisher
Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1
Reference31 articles.
1. Aĺvarez L, Guañabens N, Peris P, et al. The clinical uti lity of biochemical markers of bone remodeling. Med Clin (Barc). 1999;112(13):517–518. PMID: 10353122.
2. Taipaleenmäki H, Browne G, Akech J, et al. Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease. Cancer Res. 2015;75(7):1433–1444. PMID: 25634212. PMCID: PMC4383679. http://doi.org/10.1158/0008-5472.CAN-14-1026
3. Devys A, Lortholary A, Audran M. PTHrP and breast cancer. Bull Cancer. 2001;88(11):1075–1080. PMID: 11741801.
4. Washam CL, Byrum SD, Leitzel K, et al. Identification of PTHrP(12–48) as a plasma biomarker associated with breast cancer bone metastasis. Cancer Epidemiol Biomarkers Prev. 2013;22(5):972–983. PMID: 23462923. PMCID: PMC3651837. Http://doi.org/10.1158/1055-9965.EPI-12-1318-T
5. Kamalakar A, Washam CL, Akel NS, et al. PTHrP(12–48) modulates the bone marrow microenvironment and suppresses human osteoclast differentiation and lifespan. J Bone Miner Res. 2017;32:1421–1431. PMID: 28370412. PMCID: PMC5518789. http://doi.org/10.1002/jbmr.3142